Literature DB >> 23999825

Effect of the cytokine levels in serum on osteosarcoma.

Hong Xiao1, Ling Chen, Gang Luo, Haihang Son, James H Prectoni, Wenjie Zheng.   

Abstract

Osteosarcoma (OS) is the most common malignant bone tumor in patients under 20 years old. Studies have shown that cytokines play important roles in regulating immune responses in OS. In the current study, we investigated the effect of cytokines on OS by assessing serum cytokine profiles. Serum levels of 11 cytokines were measured by multiplex protein arrays in 58 patients with OS and 72 healthy controls. Results showed that serum levels of interleukin 1 receptor antagonist (IL-1Ra), IL-6, IL-8, and tumor necrosis factor-alpha (TNF-α) were significantly increased in patients than in controls (2.5-fold, 2.4-fold, 2.7-fold, and 2.1-fold, respectively). When comparing the expression of cytokines in OS patients with different clinical parameters, cases with osteoblastic subtype revealed increased level of IL-6 than patients with other subtypes (p < 0.05); cases with metastasis demonstrated significantly higher level of TNF-α than those without metastasis (p < 0.05), whereas OS patients whose tumor size were bigger than 8 cm presented elevated levels of IL-8 and TNF-α than those with small tumor size (p < 0.05 and p < 0.05, respectively). These data indicated that IL-1Ra, IL-6, IL-8, and TNF-α were associated with increased risk of OS, in which IL-8 and TNF-α may be further correlated with the progression of this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23999825     DOI: 10.1007/s13277-013-1136-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells.

Authors:  Chih-Hsin Tang; Cheng-Fong Chen; Wei-Ming Chen; Yi-Chin Fong
Journal:  J Biol Chem       Date:  2011-01-28       Impact factor: 5.157

Review 2.  The price of immunity.

Authors:  Romina S Goldszmid; Giorgio Trinchieri
Journal:  Nat Immunol       Date:  2012-09-18       Impact factor: 25.606

3.  Cell adhesion molecule 1 is a new osteoblastic cell adhesion molecule and a diagnostic marker for osteosarcoma.

Authors:  Takao Inoue; Man Hagiyama; Eisuke Enoki; Minami A Sakurai; Akihiro Tan; Tomohiko Wakayama; Shoichi Iseki; Yoshinori Murakami; Kanji Fukuda; Chiaki Hamanishi; Akihiko Ito
Journal:  Life Sci       Date:  2012-11-07       Impact factor: 5.037

4.  Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation.

Authors:  Peter A Keyel; Olga A Tkacheva; Adriana T Larregina; Russell D Salter
Journal:  J Immunol       Date:  2012-09-26       Impact factor: 5.422

Review 5.  Current treatment considerations in metastatic renal cell carcinoma.

Authors:  Housam Haddad; Brian I Rini
Journal:  Curr Treat Options Oncol       Date:  2012-06

6.  Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma.

Authors:  Daniel Baumhoer; Jan Smida; Stephanie Zillmer; Michael Rosemann; Michael J Atkinson; Peter J Nelson; Gernot Jundt; Irene von Luettichau; Michaela Nathrath
Journal:  Mod Pathol       Date:  2011-12-16       Impact factor: 7.842

Review 7.  The interleukin-8 pathway in cancer.

Authors:  David J J Waugh; Catherine Wilson
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma.

Authors:  Huey-En Tzeng; Chun-Hao Tsai; Zi-Ling Chang; Chen-Ming Su; Shih-Wei Wang; Wen-Li Hwang; Chih-Hsin Tang
Journal:  Biochem Pharmacol       Date:  2012-12-05       Impact factor: 5.858

Review 9.  Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism.

Authors:  C A Dinarello
Journal:  Int J Tissue React       Date:  1992

10.  IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.

Authors:  Chi-Wen Lo; Min-Wei Chen; Michael Hsiao; Shiuan Wang; Chi-An Chen; Sheng-Mou Hsiao; Jeng-Shou Chang; Tsung-Ching Lai; Stefan Rose-John; Min-Liang Kuo; Lin-Hung Wei
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

View more
  12 in total

1.  Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation.

Authors:  Sofia Avnet; Gemma Di Pompo; Tokuhiro Chano; Costantino Errani; Arig Ibrahim-Hashim; Robert J Gillies; Davide Maria Donati; Nicola Baldini
Journal:  Int J Cancer       Date:  2017-03-15       Impact factor: 7.396

2.  Association of -308G/A and -238G/A polymorphisms of TNF-α and osteosarcoma risk.

Authors:  Zhongwei Zhao; Xiangyu Tang; Kai Song; Xiang Li; Yonggang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 3.  Association of genetic polymorphisms with osteosarcoma risk: a meta-analysis.

Authors:  Zhenyu Bian; Qifang He; Xuepeng Wang; Maoqiang Li; Liulong Zhu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Association of interleukin 16 gene polymorphisms and plasma IL16 level with osteosarcoma risk.

Authors:  Yu-Jin Tang; Jun-Li Wang; Ke-Gong Xie; Chang-Gong Lan
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

5.  Lack of association between platelet indices and disease stage in osteosarcoma at diagnosis.

Authors:  Hongtao Li; Yonggang Wang; Zimei Liu; Yuan Yuan; Wentao Huang; Na Zhang; Aina He; Zan Shen; Yuanjue Sun; Yang Yao
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

6.  IL-6 Promotes Cancer Stemness and Oncogenicity in U2OS and MG-63 Osteosarcoma Cells by Upregulating the OPN-STAT3 Pathway.

Authors:  Chuan Zhang; Kun Ma; Wu-Yin Li
Journal:  J Cancer       Date:  2019-10-21       Impact factor: 4.207

Review 7.  Sarcoma treatment in the era of molecular medicine.

Authors:  Thomas Gp Grünewald; Marta Alonso; Sofia Avnet; Ana Banito; Stefan Burdach; Florencia Cidre-Aranaz; Gemma Di Pompo; Martin Distel; Heathcliff Dorado-Garcia; Javier Garcia-Castro; Laura González-González; Agamemnon E Grigoriadis; Merve Kasan; Christian Koelsche; Manuela Krumbholz; Fernando Lecanda; Silvia Lemma; Dario L Longo; Claudia Madrigal-Esquivel; Álvaro Morales-Molina; Julian Musa; Shunya Ohmura; Benjamin Ory; Miguel Pereira-Silva; Francesca Perut; Rene Rodriguez; Carolin Seeling; Nada Al Shaaili; Shabnam Shaabani; Kristina Shiavone; Snehadri Sinha; Eleni M Tomazou; Marcel Trautmann; Maria Vela; Yvonne Mh Versleijen-Jonkers; Julia Visgauss; Marta Zalacain; Sebastian J Schober; Andrej Lissat; William R English; Nicola Baldini; Dominique Heymann
Journal:  EMBO Mol Med       Date:  2020-10-13       Impact factor: 12.137

8.  IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.

Authors:  Tanmay M Shekhar; Mark A Miles; Ankita Gupte; Scott Taylor; Brianna Tascone; Carl R Walkley; Christine J Hawkins
Journal:  Oncotarget       Date:  2016-06-07

9.  Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.

Authors:  Chuan Zhang; Kun Ma; Wu-Yin Li
Journal:  Drug Des Devel Ther       Date:  2019-12-04       Impact factor: 4.162

10.  hsa_circ0021347 as a Potential Target Regulated by B7-H3 in Modulating the Malignant Characteristics of Osteosarcoma.

Authors:  Ling Wang; Guo-Chuan Zhang; Fu-Biao Kang; Long Zhang; Ying-Ze Zhang
Journal:  Biomed Res Int       Date:  2019-12-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.